956317-40-1 Usage
Uses
Used in Chemical Industry:
Hexahydro-6-hydroxy-1H-1,4-diazepine-1-carboxylic acid tert-butyl ester is used as an intermediate in the synthesis of various chemical compounds, contributing to the development of new materials and products.
Used in Pharmaceutical Industry:
Hexahydro-6-hydroxy-1H-1,4-diazepine-1-carboxylic acid tert-butyl ester is used as a building block in the design and synthesis of pharmaceutical compounds, potentially leading to the discovery of new drugs with therapeutic benefits.
Ongoing Research and Development:
The properties and uses of Hexahydro-6-hydroxy-1H-1,4-diazepine-1-carboxylic acid tert-butyl ester are the subject of ongoing research and development efforts, aiming to further explore its potential applications and optimize its synthesis for industrial and medicinal purposes.
Check Digit Verification of cas no
The CAS Registry Mumber 956317-40-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,6,3,1 and 7 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 956317-40:
(8*9)+(7*5)+(6*6)+(5*3)+(4*1)+(3*7)+(2*4)+(1*0)=191
191 % 10 = 1
So 956317-40-1 is a valid CAS Registry Number.
956317-40-1Relevant academic research and scientific papers
AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
-
, (2015/07/22)
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
-
, (2015/09/22)
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
DIAZEPAN OREXIN RECEPTOR ANTAGONISTS
-
Page/Page column 34, (2008/06/13)
The present invention is directed to diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The inven
